A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF

A. Muto, M. Kizaki, C. Kawamura, H. Matsushita, Y. Fukuchi, A. Umezawa, T. Yamada, J. Hata, N. Hozumi, K. Yamato, M. Ito, Y. Ueyama, Y. Ikeda

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Arsenic trioxide (AS2O3) effectively induces clinical remission via apoptosis in relapsed acute promyelocytic leukemia (APL). However, because this new anti-leukemic drug is also considered to be a poison, its possible adverse effects are a highly important issue related to its clinical use. We here investigated, both in vitro and in vivo, the effects of a combination of As2O3 and GM-CSF as a novel therapeutic approach for the treatment of APL. Treatment of both retinoic acid (RA)-sensitive and -resistant APL cell lines (NB4 and UF-1 cells, respectively), as well as primary APL cells with a combination of As2O3 and GM-CSF for 4 days resulted in inducing differentiation, but not apoptosis, to mature granulocytes. In addition, a combination of both agents induced degradation of the PML/RARα protein. GM-CSF was found to be associated with increased tyrosine phosphorylation of Jak2 kinase in both NB4 and UF-1 cells, and a specific inhibitor of Jak2, AG490, completely blocked the ability of GM-CSF to prevent apoptosis and induce differentiation of As2O3-treated UF-1 cells. In in vivo analysis, As2O3 induced differentiation of APL cells in a RA-resistant APL model of human GM-CSF-producing transgenic SCID mice that had a high level of human GM-CSF in their sera. In contrast, As2O3 alone diminished tumors in UF-1 cells transplanted into NOD/SCID mice via induction of apoptosis. In conclusion, a combination of As2O3 and GM-CSF appears to be a novel differentiation-inducing therapy in patients with APL, including relapsed or RA-resistant cases.

Original languageEnglish
Pages (from-to)1176-1184
Number of pages9
JournalLeukemia
Volume15
Issue number8
DOIs
Publication statusPublished - 2001

Fingerprint

Acute Promyelocytic Leukemia
Granulocyte-Macrophage Colony-Stimulating Factor
Tretinoin
Apoptosis
SCID Mice
Therapeutics
Inbred NOD Mouse
Poisons
arsenic trioxide
Granulocytes
Transgenic Mice
Tyrosine
Phosphotransferases
Phosphorylation
Cell Line
Serum
Pharmaceutical Preparations

Keywords

  • Acute promyelocytic leukemia (APL)
  • Apoptosis
  • Arsenic trioxide
  • Differentiation
  • GM-CSF

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Muto, A., Kizaki, M., Kawamura, C., Matsushita, H., Fukuchi, Y., Umezawa, A., ... Ikeda, Y. (2001). A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia, 15(8), 1176-1184. https://doi.org/10.1038/sj.leu.2402162

A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. / Muto, A.; Kizaki, M.; Kawamura, C.; Matsushita, H.; Fukuchi, Y.; Umezawa, A.; Yamada, T.; Hata, J.; Hozumi, N.; Yamato, K.; Ito, M.; Ueyama, Y.; Ikeda, Y.

In: Leukemia, Vol. 15, No. 8, 2001, p. 1176-1184.

Research output: Contribution to journalArticle

Muto, A, Kizaki, M, Kawamura, C, Matsushita, H, Fukuchi, Y, Umezawa, A, Yamada, T, Hata, J, Hozumi, N, Yamato, K, Ito, M, Ueyama, Y & Ikeda, Y 2001, 'A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF', Leukemia, vol. 15, no. 8, pp. 1176-1184. https://doi.org/10.1038/sj.leu.2402162
Muto, A. ; Kizaki, M. ; Kawamura, C. ; Matsushita, H. ; Fukuchi, Y. ; Umezawa, A. ; Yamada, T. ; Hata, J. ; Hozumi, N. ; Yamato, K. ; Ito, M. ; Ueyama, Y. ; Ikeda, Y. / A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. In: Leukemia. 2001 ; Vol. 15, No. 8. pp. 1176-1184.
@article{e5eb1d00802a405cbbeca8c54c8efffe,
title = "A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF",
abstract = "Arsenic trioxide (AS2O3) effectively induces clinical remission via apoptosis in relapsed acute promyelocytic leukemia (APL). However, because this new anti-leukemic drug is also considered to be a poison, its possible adverse effects are a highly important issue related to its clinical use. We here investigated, both in vitro and in vivo, the effects of a combination of As2O3 and GM-CSF as a novel therapeutic approach for the treatment of APL. Treatment of both retinoic acid (RA)-sensitive and -resistant APL cell lines (NB4 and UF-1 cells, respectively), as well as primary APL cells with a combination of As2O3 and GM-CSF for 4 days resulted in inducing differentiation, but not apoptosis, to mature granulocytes. In addition, a combination of both agents induced degradation of the PML/RARα protein. GM-CSF was found to be associated with increased tyrosine phosphorylation of Jak2 kinase in both NB4 and UF-1 cells, and a specific inhibitor of Jak2, AG490, completely blocked the ability of GM-CSF to prevent apoptosis and induce differentiation of As2O3-treated UF-1 cells. In in vivo analysis, As2O3 induced differentiation of APL cells in a RA-resistant APL model of human GM-CSF-producing transgenic SCID mice that had a high level of human GM-CSF in their sera. In contrast, As2O3 alone diminished tumors in UF-1 cells transplanted into NOD/SCID mice via induction of apoptosis. In conclusion, a combination of As2O3 and GM-CSF appears to be a novel differentiation-inducing therapy in patients with APL, including relapsed or RA-resistant cases.",
keywords = "Acute promyelocytic leukemia (APL), Apoptosis, Arsenic trioxide, Differentiation, GM-CSF",
author = "A. Muto and M. Kizaki and C. Kawamura and H. Matsushita and Y. Fukuchi and A. Umezawa and T. Yamada and J. Hata and N. Hozumi and K. Yamato and M. Ito and Y. Ueyama and Y. Ikeda",
year = "2001",
doi = "10.1038/sj.leu.2402162",
language = "English",
volume = "15",
pages = "1176--1184",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF

AU - Muto, A.

AU - Kizaki, M.

AU - Kawamura, C.

AU - Matsushita, H.

AU - Fukuchi, Y.

AU - Umezawa, A.

AU - Yamada, T.

AU - Hata, J.

AU - Hozumi, N.

AU - Yamato, K.

AU - Ito, M.

AU - Ueyama, Y.

AU - Ikeda, Y.

PY - 2001

Y1 - 2001

N2 - Arsenic trioxide (AS2O3) effectively induces clinical remission via apoptosis in relapsed acute promyelocytic leukemia (APL). However, because this new anti-leukemic drug is also considered to be a poison, its possible adverse effects are a highly important issue related to its clinical use. We here investigated, both in vitro and in vivo, the effects of a combination of As2O3 and GM-CSF as a novel therapeutic approach for the treatment of APL. Treatment of both retinoic acid (RA)-sensitive and -resistant APL cell lines (NB4 and UF-1 cells, respectively), as well as primary APL cells with a combination of As2O3 and GM-CSF for 4 days resulted in inducing differentiation, but not apoptosis, to mature granulocytes. In addition, a combination of both agents induced degradation of the PML/RARα protein. GM-CSF was found to be associated with increased tyrosine phosphorylation of Jak2 kinase in both NB4 and UF-1 cells, and a specific inhibitor of Jak2, AG490, completely blocked the ability of GM-CSF to prevent apoptosis and induce differentiation of As2O3-treated UF-1 cells. In in vivo analysis, As2O3 induced differentiation of APL cells in a RA-resistant APL model of human GM-CSF-producing transgenic SCID mice that had a high level of human GM-CSF in their sera. In contrast, As2O3 alone diminished tumors in UF-1 cells transplanted into NOD/SCID mice via induction of apoptosis. In conclusion, a combination of As2O3 and GM-CSF appears to be a novel differentiation-inducing therapy in patients with APL, including relapsed or RA-resistant cases.

AB - Arsenic trioxide (AS2O3) effectively induces clinical remission via apoptosis in relapsed acute promyelocytic leukemia (APL). However, because this new anti-leukemic drug is also considered to be a poison, its possible adverse effects are a highly important issue related to its clinical use. We here investigated, both in vitro and in vivo, the effects of a combination of As2O3 and GM-CSF as a novel therapeutic approach for the treatment of APL. Treatment of both retinoic acid (RA)-sensitive and -resistant APL cell lines (NB4 and UF-1 cells, respectively), as well as primary APL cells with a combination of As2O3 and GM-CSF for 4 days resulted in inducing differentiation, but not apoptosis, to mature granulocytes. In addition, a combination of both agents induced degradation of the PML/RARα protein. GM-CSF was found to be associated with increased tyrosine phosphorylation of Jak2 kinase in both NB4 and UF-1 cells, and a specific inhibitor of Jak2, AG490, completely blocked the ability of GM-CSF to prevent apoptosis and induce differentiation of As2O3-treated UF-1 cells. In in vivo analysis, As2O3 induced differentiation of APL cells in a RA-resistant APL model of human GM-CSF-producing transgenic SCID mice that had a high level of human GM-CSF in their sera. In contrast, As2O3 alone diminished tumors in UF-1 cells transplanted into NOD/SCID mice via induction of apoptosis. In conclusion, a combination of As2O3 and GM-CSF appears to be a novel differentiation-inducing therapy in patients with APL, including relapsed or RA-resistant cases.

KW - Acute promyelocytic leukemia (APL)

KW - Apoptosis

KW - Arsenic trioxide

KW - Differentiation

KW - GM-CSF

UR - http://www.scopus.com/inward/record.url?scp=17944372810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944372810&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402162

DO - 10.1038/sj.leu.2402162

M3 - Article

C2 - 11480559

AN - SCOPUS:17944372810

VL - 15

SP - 1176

EP - 1184

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -